Heron Therapeutics is trading at $0.33, up 12.49%, in pre-market with no confirmed catalyst.
- No new company-specific announcement explaining the October 23 pre-market rise was identified; Heron’s investor-relations releases list its August 10 second-quarter results as the latest release.
- The prior session’s selloff coincided with broader risk-off headlines, but the supplied October 23 market context is mixed and does not establish a cause for this gain.